A Second-Order Simulation Model of the Cost-Effectiveness of Managing Dyspepsia in the United States

Pelham M. Barton, Paul Moayyedi, Nicholas J. Talley, Nimish B. Vakil and Brendan C. Delaney
Additional contact information
Pelham M. Barton: Health Economics Facility University of Birmingham, UK
Paul Moayyedi: Department of Gastroenterology, McMaster University, Hamilton, Ontario, Canada
Nicholas J. Talley: Center for Enteric Neurosciences and Translational Epidemiological Research (CENTER), Mayo Clinic College of Medicine, Rochester, Minnesota, Department of Medicine, University of Sydney, Sydney, Australia
Nimish B. Vakil: University of Wisconsin Medical School, Milwaukee, Wisconsin
Brendan C. Delaney: Department of Primary Care and General Practice University of Birmingham, UK, b.c.delaney@bham.ac.uk

Medical Decision Making, 2008, vol. 28, issue 1, 44-55

Abstract: Background. The ``gold-standard'' evidence of effectiveness for a clinical practice guideline is the randomized controlled trial (RCT), although RCTs have a limited ability to explore potential management strategies for a chronic disease where these interact over time. Modeling can be used to fill this gap, and models have become increasingly complex, with both dynamic sampling and representation of second-order uncertainty to provide more precise estimates. However, both simulation modeling and probabilistic sensitivity analysis are rarely used together. The objective of this study was to explore uncertainty in controversial areas of the 2005 American Gastroenterology Association position statement on the management of dyspepsia. Methods. Individual sampling model, incorporating a second-order probabilistic sensitivity analysis. Population. US adult patients presenting in primary care with dyspepsia. Interventions compared: empirical acid suppression, test and treat for Helicobacter pylori, initial endoscopy, acid suppression then endoscopy, test and treat then proton pump inhibitor (PPI) then endoscopy. Outcomes. Cost-effectiveness, quality-adjusted life years, and costs in US dollars from a societal perspective, measured over a 5-year period. Data sources: mainly Cochrane meta-analyses. Results. Endoscopy was dominated at all ages by other strategies. PPI therapy was the most cost-effective strategy in 30-year-olds with a low prevalence of H. pylori. In 60-year-olds, H. pylori test and treat was the most cost-effective option. Conclusions. Acid suppression alone was more cost-effective than either endoscopy or H. pylori test and treat in younger dyspepsia patients with a low prevalence of infection.

Keywords: computer simulation; dyspepsia; cost-benefit analysis (search for similar items in EconPapers)
Date: 2008
References: View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://journals.sagepub.com/doi/10.1177/0272989X07309644 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:sae:medema:v:28:y:2008:i:1:p:44-55

DOI: 10.1177/0272989X07309644

Access Statistics for this article

More articles in Medical Decision Making
Bibliographic data for series maintained by SAGE Publications ().